KemPharm, Inc. (KMPH)
| Market Cap | 178.89M |
| Revenue (ttm) | 12.30M |
| Net Income (ttm) | -13.94M |
| Shares Out | 4.43M |
| EPS (ttm) | -4.14 |
| PE Ratio | n/a |
| Forward PE | 2.09 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $16.71 |
| Previous Close | $9.43 |
| Change ($) | 7.28 |
| Change (%) | 77.20% |
| Day's Open | 15.50 |
| Day's Range | 15.00 - 18.12 |
| Day's Volume | 26,393,220 |
| 52-Week Range | 0.18 - 18.12 |
The FDA has approved KemPharm Inc's (NASDAQ: KMPH) market application for Azstarys (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity di...
Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
Financial Restructuring and Nasdaq Re-Listing Process Completed
Combination of Oral and Poster Presentations Scheduled for January 15, 2021
CELEBRATION, Fla., Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today a...
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021
CELEBRATION, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today an...
CELEBRATION, Fla., Dec. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today an...
CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today an...
Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET
IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug Candidate Added to Pipeline , Targeting Rare CNS Disease , Idiopathic Hypersomnia (IH)
Online Event Scheduled for Wednesday, December 2, 2020 at 10:00 a.m., ET
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4 : 3 0 p.m. ET
Special Meeting of Stockholders Rescheduled to Tues day , Nov 17, 2020, 8:00 a.m. ET
CELEBRATION, Fla., Oct. 22, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today an...
New agreement provides additional revenue potentially through Q1 2022
4 Small Drug Stocks to Look Out For Amid Coronavirus Uncertainty
CELEBRATION, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (KemPharm, or the Company) (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of ...
Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment
Presentations to Highlight Corporate, Regulatory and Pipeline Advancements Presentations to Highlight Corporate, Regulatory and Pipeline Advancements
CELEBRATION, Fla., Aug. 14, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET Conference Call and Live Audio Webcast with Slide Presentation Scheduled f...
New Patent Issuance Extends SDX Patent Life for an Additional Five Years until 2037
CELEBRATION, Fla., June 18, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today ...
We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.
KemPharma (KMPH) delivered earnings and revenue surprises of -1100.00% and -63.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q1 2020 Results - Earnings Call Transcript
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m. ET
Corium, GPC’s portfolio company, to lead all commercialization activities for KP415
If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products
KemPharma (KMPH) delivered earnings and revenue surprises of -28.57% and -62.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today
Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021; Expected to Extend Cash Runway to New Maturity Date
KemPharm, Inc. (KMPH) CEO Travis Mickle on Q3 2019 Results - Earnings Call Transcript
Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink
CELEBRATION, Fla., Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, anno...
CELEBRATION, Fla., Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, anno...
CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales
Investors need to pay close attention to KemPharm (KMPH) stock based on the movements in the options market lately.
KemPharm on Wednesday gave a presentation on its Apadaz commercialization progress, which is fairly exciting.
About KMPH
KemPharm, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ.... [Read more...]
| Industry Biotechnology | IPO Date Apr 16, 2015 |
| CEO Travis Mickle | Employees 22 |
| Stock Exchange NASDAQ | Ticker Symbol KMPH |
Analyst Forecasts
The average 12-month stock price forecast for KemPharm is 26.00, which is an increase of 55.60% from the latest price.